TNF receptor associated periodic syndrome: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (21 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{Sahar}} | ||
{{SK}} Tumor necrosis factor receptor-associated periodic syndrome (TRAPS); | {{SK}} [[Tumor necrosis factor receptor-associated periodic syndrome]] ([[Tumor necrosis factor receptor-associated periodic syndrome|TRAPS]]); [[Familial Hibernian fever]]; [[Familial Hibernian fever|FHF]]; [[Familial Caledonian fever]] | ||
==Overview== | ==Overview== | ||
'''TNF receptor-associated periodic syndrome''' (also known as '''TRAPS''' or '''familial Hibernian fever''') is a [[periodic fever syndrome]] associated with mutation in a [[Receptor (biochemistry)|receptor]] for the [[molecule]] [[Tumor necrosis factors|tumor necrosis factor]] ([[TNF]]). Since this disease first described in Ireland, it was called Hibernian fever in reference to the ancient Latin name for Ireland, Hibernia. | '''TNF receptor-associated periodic syndrome''' (also known as '''TRAPS''' or '''familial Hibernian fever''') is a [[periodic fever syndrome]] associated with [[mutation]] in a [[Receptor (biochemistry)|receptor]] for the [[molecule]] [[Tumor necrosis factors|tumor necrosis factor]] ([[TNF]]). Since this disease first described in Ireland, it was called Hibernian fever in reference to the ancient Latin name for Ireland, Hibernia. | ||
==Historical Perspective== | ==Historical Perspective== | ||
*TNF receptor-associated periodic syndrome was first described by Dr. Williamson in 1982 in an Irish-Scottish family affected by an [[autosomal dominant]] pattern [[disorder]].<ref>{{Cite journal | *TNF receptor-associated periodic syndrome was first described by Dr. Williamson in 1982 in an Irish-Scottish family affected by an [[autosomal dominant]] pattern [[disorder]].<ref>{{Cite journal | ||
| Line 18: | Line 18: | ||
| pmid = 7156325 | | pmid = 7156325 | ||
}}</ref> | }}</ref> | ||
*The association between the [[TNFRSF1A]] [[gene]] locus and TNF receptor-associated periodic syndrome was made in 1998.<ref name="McDermottOgunkolade1998">{{cite journal|last1=McDermott|first1=Michael F.|last2=Ogunkolade|first2=B. William|last3=McDermott|first3=Elizabeth M.|last4=Jones|first4=Lisa C.|last5=Wan|first5=Ying|last6=Quane|first6=Kathleen A.|last7=McCarthy|first7=John|last8=Phelan|first8=Mark|last9=Molloy|first9=Michael G.|last10=Powell|first10=Richard J.|last11=Amos|first11=Christopher I.|last12=Hitman|first12=Graham A.|title=Linkage of Familial Hibernian Fever to Chromosome 12p13|journal=The American Journal of Human Genetics|volume=62|issue=6|year=1998|pages=1446–1451|issn=00029297|doi=10.1086/301886}}</ref> | *The association between the [[TNFRSF1A]] [[gene]] [[locus]] and TNF receptor-associated periodic syndrome was made in 1998.<ref name="McDermottOgunkolade1998">{{cite journal|last1=McDermott|first1=Michael F.|last2=Ogunkolade|first2=B. William|last3=McDermott|first3=Elizabeth M.|last4=Jones|first4=Lisa C.|last5=Wan|first5=Ying|last6=Quane|first6=Kathleen A.|last7=McCarthy|first7=John|last8=Phelan|first8=Mark|last9=Molloy|first9=Michael G.|last10=Powell|first10=Richard J.|last11=Amos|first11=Christopher I.|last12=Hitman|first12=Graham A.|title=Linkage of Familial Hibernian Fever to Chromosome 12p13|journal=The American Journal of Human Genetics|volume=62|issue=6|year=1998|pages=1446–1451|issn=00029297|doi=10.1086/301886}}</ref> | ||
*In 2003, Dr. Weyhreter was the first to use [[etanercept]] (a fusion protein of the extracellular domain of TNFRSF1A and the [[Fc receptor|Fc]] portion of [[IgG]]1) for the treatment of TRAPS, which results successful treatment of the patient.<ref name="WeyhreterSchwartz2003">{{cite journal|last1=Weyhreter|first1=Heike|last2=Schwartz|first2=Marianne|last3=Kristensen|first3=Tim D.|last4=Valerius|first4=Niels H.|last5=Paerregaard|first5=Anders|title=A new mutation causing autosomal dominant periodic fever syndrome in a Danish family|journal=The Journal of Pediatrics|volume=142|issue=2|year=2003|pages=191–193|issn=00223476|doi=10.1067/mpd.2003.15}}</ref> | *In 2003, Dr. Weyhreter was the first to use [[etanercept]] (a [[fusion protein]] of the [[extracellular]] domain of TNFRSF1A and the [[Fc receptor|Fc]] portion of [[IgG]]1) for the treatment of TRAPS, which results successful [[treatment]] of the [[patient]].<ref name="WeyhreterSchwartz2003">{{cite journal|last1=Weyhreter|first1=Heike|last2=Schwartz|first2=Marianne|last3=Kristensen|first3=Tim D.|last4=Valerius|first4=Niels H.|last5=Paerregaard|first5=Anders|title=A new mutation causing autosomal dominant periodic fever syndrome in a Danish family|journal=The Journal of Pediatrics|volume=142|issue=2|year=2003|pages=191–193|issn=00223476|doi=10.1067/mpd.2003.15}}</ref> | ||
==Classification== | ==Classification== | ||
There is no established system for the classification of TNF receptor associated periodic syndrome. | *There is no established system for the [[classification]] of TNF receptor associated periodic syndrome. | ||
==Pathophysiology== | ==Pathophysiology== | ||
*TNF receptor associated periodic syndrome is an [[autosomal dominant]] inherited [[disorder]] due to [[mutation]] in the [[Tumor necrosis factor-alpha|TNF]] [[Receptor]] Super Family 1A (TNFRSF1A) [[gene]].<ref>{{Cite journal | *TNF receptor associated periodic syndrome is an [[autosomal dominant]] inherited [[disorder]] due to [[mutation]] in the [[Tumor necrosis factor-alpha|TNF]] [[Receptor]] Super Family 1A (TNFRSF1A) [[gene]].<ref>{{Cite journal | ||
| Line 34: | Line 34: | ||
| pmid = 10199409 | | pmid = 10199409 | ||
}}</ref> | }}</ref> | ||
*Mutation in the gene is associated with abnormally structured TNF receptor which leads to impaired TNF-a binding and subsequent abnormal function of this factor in apoptosis and NF-κB pathway. However, the exact mechanisms causing febrile episodes remain to be cleared.<ref name="NedjaiHitman2008">{{cite journal|last1=Nedjai|first1=Belinda|last2=Hitman|first2=Graham A.|last3=Yousaf|first3=Nasim|last4=Chernajovsky|first4=Yuti|last5=Stjernberg-Salmela|first5=Susanna|last6=Pettersson|first6=Tom|last7=Ranki|first7=Annamari|last8=Hawkins|first8=Philip N.|last9=Arkwright|first9=Peter D.|last10=McDermott|first10=Michael F.|last11=Turner|first11=Mark D.|title=Abnormal tumor necrosis factor receptor I cell surface expression and NF-κB activation in tumor necrosis factor receptor–associated periodic syndrome|journal=Arthritis & Rheumatism|volume=58|issue=1|year=2008|pages=273–283|issn=00043591|doi=10.1002/art.23123}}</ref><ref name="D'OsualdoFerlito2006">{{cite journal|last1=D'Osualdo|first1=Andrea|last2=Ferlito|first2=Francesca|last3=Prigione|first3=Ignazia|last4=Obici|first4=Laura|last5=Meini|first5=Antonella|last6=Zulian|first6=Francesco|last7=Pontillo|first7=Alessandra|last8=Corona|first8=Fabrizia|last9=Barcellona|first9=Roberto|last10=Duca|first10=Marco Di|last11=Santamaria|first11=Giuseppe|last12=Traverso|first12=Francesco|last13=Picco|first13=Paolo|last14=Baldi|first14=Maurizia|last15=Plebani|first15=Alessandro|last16=Ravazzolo|first16=Roberto|last17=Ceccherini|first17=Isabella|last18=Martini|first18=Alberto|last19=Gattorno|first19=Marco|title=Neutrophils from patients withTNFRSF1A mutations display resistance to tumor necrosis factor–induced apoptosis: Pathogenetic and clinical implications|journal=Arthritis & Rheumatism|volume=54|issue=3|year=2006|pages=998–1008|issn=0004-3591|doi=10.1002/art.21657}}</ref><ref name="ChurchmanChurch2007">{{cite journal|last1=Churchman|first1=S M|last2=Church|first2=L D|last3=Savic|first3=S|last4=Coulthard|first4=L R|last5=Hayward|first5=B|last6=Nedjai|first6=B|last7=Turner|first7=M D|last8=Mathews|first8=R J|last9=Baguley|first9=E|last10=Hitman|first10=G A|last11=Gooi|first11=H C|last12=Wood|first12=P M D|last13=Emery|first13=P|last14=McDermott|first14=M F|title=A novel TNFRSF1A splice mutation associated with increased nuclear factor appaB (NF- B) transcription factor activation in patients with tumour necrosis factor receptor associated periodic syndrome (TRAPS)|journal=Annals of the Rheumatic Diseases|volume=67|issue=11|year=2007|pages=1589–1595|issn=0003-4967|doi=10.1136/ard.2007.078667}}</ref> | *[[Mutation]] in the [[gene]] is associated with abnormally structured [[TNF receptor]] which leads to impaired [[TNF-alpha|TNF-a]] binding and subsequent abnormal function of this factor in [[apoptosis]] and [[NF-κB]] pathway. However, the exact mechanisms causing [[febrile]] episodes remain to be cleared.<ref name="NedjaiHitman2008">{{cite journal|last1=Nedjai|first1=Belinda|last2=Hitman|first2=Graham A.|last3=Yousaf|first3=Nasim|last4=Chernajovsky|first4=Yuti|last5=Stjernberg-Salmela|first5=Susanna|last6=Pettersson|first6=Tom|last7=Ranki|first7=Annamari|last8=Hawkins|first8=Philip N.|last9=Arkwright|first9=Peter D.|last10=McDermott|first10=Michael F.|last11=Turner|first11=Mark D.|title=Abnormal tumor necrosis factor receptor I cell surface expression and NF-κB activation in tumor necrosis factor receptor–associated periodic syndrome|journal=Arthritis & Rheumatism|volume=58|issue=1|year=2008|pages=273–283|issn=00043591|doi=10.1002/art.23123}}</ref><ref name="D'OsualdoFerlito2006">{{cite journal|last1=D'Osualdo|first1=Andrea|last2=Ferlito|first2=Francesca|last3=Prigione|first3=Ignazia|last4=Obici|first4=Laura|last5=Meini|first5=Antonella|last6=Zulian|first6=Francesco|last7=Pontillo|first7=Alessandra|last8=Corona|first8=Fabrizia|last9=Barcellona|first9=Roberto|last10=Duca|first10=Marco Di|last11=Santamaria|first11=Giuseppe|last12=Traverso|first12=Francesco|last13=Picco|first13=Paolo|last14=Baldi|first14=Maurizia|last15=Plebani|first15=Alessandro|last16=Ravazzolo|first16=Roberto|last17=Ceccherini|first17=Isabella|last18=Martini|first18=Alberto|last19=Gattorno|first19=Marco|title=Neutrophils from patients withTNFRSF1A mutations display resistance to tumor necrosis factor–induced apoptosis: Pathogenetic and clinical implications|journal=Arthritis & Rheumatism|volume=54|issue=3|year=2006|pages=998–1008|issn=0004-3591|doi=10.1002/art.21657}}</ref><ref name="ChurchmanChurch2007">{{cite journal|last1=Churchman|first1=S M|last2=Church|first2=L D|last3=Savic|first3=S|last4=Coulthard|first4=L R|last5=Hayward|first5=B|last6=Nedjai|first6=B|last7=Turner|first7=M D|last8=Mathews|first8=R J|last9=Baguley|first9=E|last10=Hitman|first10=G A|last11=Gooi|first11=H C|last12=Wood|first12=P M D|last13=Emery|first13=P|last14=McDermott|first14=M F|title=A novel TNFRSF1A splice mutation associated with increased nuclear factor appaB (NF- B) transcription factor activation in patients with tumour necrosis factor receptor associated periodic syndrome (TRAPS)|journal=Annals of the Rheumatic Diseases|volume=67|issue=11|year=2007|pages=1589–1595|issn=0003-4967|doi=10.1136/ard.2007.078667}}</ref> | ||
*Another | *Another hypotheses is that [[mutation]] in the [[gene]] results in [[intracellular]] accumulation of the [[receptor]]. This abnormal accumulation of the [[receptor]] leads to an exaggerated [[inflammatory]] response to low levels of innate [[Stimulant|stimuli]] such as [[lipopolysaccharide]] ([[Lipopolysaccharide|LPS]]).<ref name="SimonPark2010">{{cite journal|last1=Simon|first1=A.|last2=Park|first2=H.|last3=Maddipati|first3=R.|last4=Lobito|first4=A. A.|last5=Bulua|first5=A. C.|last6=Jackson|first6=A. J.|last7=Chae|first7=J. J.|last8=Ettinger|first8=R.|last9=de Koning|first9=H. D.|last10=Cruz|first10=A. C.|last11=Kastner|first11=D. L.|last12=Komarow|first12=H.|last13=Siegel|first13=R. M.|title=Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome|journal=Proceedings of the National Academy of Sciences|volume=107|issue=21|year=2010|pages=9801–9806|issn=0027-8424|doi=10.1073/pnas.0914118107}}</ref> | ||
==Differentiating | ==Differentiating TNF receptor associated periodic syndrome from Other Diseases== | ||
* | *TNF receptor associated periodic syndrome must be differentiated from other [[diseases]] that cause [[fever]], [[abdominal pain]], and [[arthritis]], such as [[infections]], other [[Periodic fever syndrome|autoinflammatory diseases]], and [[autoimmune disorders]]. | ||
*For more information on the [[differential diagnosis]] of TNF receptor associated periodic syndrome please [[Familial mediterranean fever differential diagnosis|click here]] | |||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
*This disorder is the second most common inflammatory disorder after familial mediterranean fever (FMF). | *This [[disorder]] is the second most common [[inflammatory]] [[disorder]] after [[familial mediterranean fever]] ([[FMF]]). | ||
*The [[incidence]] of TNF receptor associated periodic syndrome is approximately 0.06 per 100,000 individuals of 16 years of age or younger worldwide.<ref name="LainkaNeudorf2009">{{cite journal|last1=Lainka|first1=E.|last2=Neudorf|first2=U.|last3=Lohse|first3=P.|last4=Timmann|first4=C.|last5=Stojanov|first5=S.|last6=Huss|first6=K.|last7=von Kries|first7=R.|last8=Niehues|first8=T.|title=Incidence of TNFRSF1A mutations in German children: epidemiological, clinical and genetic characteristics|journal=Rheumatology|volume=48|issue=8|year=2009|pages=987–991|issn=1462-0324|doi=10.1093/rheumatology/kep140}}</ref> | *The [[incidence]]/[[prevalence]] of TNF receptor associated periodic syndrome is approximately 0.06 per 100,000 individuals of 16 years of age or younger worldwide.<ref name="LainkaNeudorf2009">{{cite journal|last1=Lainka|first1=E.|last2=Neudorf|first2=U.|last3=Lohse|first3=P.|last4=Timmann|first4=C.|last5=Stojanov|first5=S.|last6=Huss|first6=K.|last7=von Kries|first7=R.|last8=Niehues|first8=T.|title=Incidence of TNFRSF1A mutations in German children: epidemiological, clinical and genetic characteristics|journal=Rheumatology|volume=48|issue=8|year=2009|pages=987–991|issn=1462-0324|doi=10.1093/rheumatology/kep140}}</ref> | ||
*TNF receptor associated periodic syndrome commonly affects individuals of 3 years of age. However, due to overlap of the symptoms with other [[disorders]] and possible misdiagnosis, it may be [[Diagnose|diagnosed]] in adolescence or adulthood. In addition, the variants with low penetrance tend to manifest later in the adult life.<ref name="CantariniIacoponi2011">{{cite journal|last1=Cantarini|first1=L.|last2=Iacoponi|first2=F.|last3=Lucherini|first3=O.M.|last4=Obici|first4=L.|last5=Brizi|first5=M.G.|last6=Cimaz|first6=R.|last7=Rigante|first7=D.|last8=Benucci|first8=M.|last9=Sebastiani|first9=G.D.|last10=Brucato|first10=A.|last11=Sabadini|first11=L.|last12=Simonini|first12=G.|last13=Giani|first13=T.|last14=Pasini|first14=F. Laghi|last15=Baldari|first15=C.T.|last16=Bellisai|first16=F.|last17=Valentini|first17=G.|last18=Bombardieri|first18=S.|last19=Paolazzi|first19=G|last20=Galeazzi|first20=M.|title=Validation of a Diagnostic Score for the Diagnosis of Autoinflammatory Diseases in Adults|journal=International Journal of Immunopathology and Pharmacology|volume=24|issue=3|year=2011|pages=695–702|issn=0394-6320|doi=10.1177/039463201102400315}}</ref> | *Approximately, 1000 cases have been reported worldwide.<ref>{{cite web |url=https://ghr.nlm.nih.gov/condition/tumor-necrosis-factor-receptor-associated-periodic-syndrome#sourcesforpage |title=TRAPS - Genetics Home Reference - NIH |format= |work= |accessdate=}}</ref> | ||
*TNF receptor associated periodic syndrome commonly affects individuals of 3 years of age. However, due to overlap of the [[Symptom|symptoms]] with other [[disorders]] and possible [[misdiagnosis]], it may be [[Diagnose|diagnosed]] in adolescence or adulthood. In addition, the variants with low penetrance tend to manifest later in the adult life.<ref name="CantariniIacoponi2011">{{cite journal|last1=Cantarini|first1=L.|last2=Iacoponi|first2=F.|last3=Lucherini|first3=O.M.|last4=Obici|first4=L.|last5=Brizi|first5=M.G.|last6=Cimaz|first6=R.|last7=Rigante|first7=D.|last8=Benucci|first8=M.|last9=Sebastiani|first9=G.D.|last10=Brucato|first10=A.|last11=Sabadini|first11=L.|last12=Simonini|first12=G.|last13=Giani|first13=T.|last14=Pasini|first14=F. Laghi|last15=Baldari|first15=C.T.|last16=Bellisai|first16=F.|last17=Valentini|first17=G.|last18=Bombardieri|first18=S.|last19=Paolazzi|first19=G|last20=Galeazzi|first20=M.|title=Validation of a Diagnostic Score for the Diagnosis of Autoinflammatory Diseases in Adults|journal=International Journal of Immunopathology and Pharmacology|volume=24|issue=3|year=2011|pages=695–702|issn=0394-6320|doi=10.1177/039463201102400315}}</ref> | |||
*Although more common in children, reports of patients developing TRAPS in old age are available.<ref name="SinožićToplak2011">{{cite journal|last1=Sinožić|first1=Dean|last2=Toplak|first2=Nataša|last3=Milotić|first3=Irena|title=Tumor Necrosis Factor Receptor-Associated Periodic Fever Syndrome in a 58-Year-Old Man|journal=Journal of Clinical Rheumatology|volume=17|issue=6|year=2011|pages=325–328|issn=1076-1608|doi=10.1097/RHU.0b013e31822e092c}}</ref> | |||
*Although, first described in Ireland, this [[disorder]] has also been reported in other countries. However, it is especially common in Western countries rather than Asian countries.<ref name="AksentijevichGalon2001">{{cite journal|last1=Aksentijevich|first1=Ivona|last2=Galon|first2=Jérôme|last3=Soares|first3=Miguel|last4=Mansfield|first4=Elizabeth|last5=Hull|first5=Keith|last6=Oh|first6=Hye-Hyun|last7=Goldbach-Mansky|first7=Raphaela|last8=Dean|first8=Jane|last9=Athreya|first9=Balu|last10=Reginato|first10=Antonio J.|last11=Henrickson|first11=Michael|last12=Pons-Estel|first12=Bernardo|last13=O’Shea|first13=John J.|last14=Kastner|first14=Daniel L.|title=The Tumor-Necrosis-Factor Receptor–Associated Periodic Syndrome: New Mutations in TNFRSF1A, Ancestral Origins, Genotype-Phenotype Studies, and Evidence for Further Genetic Heterogeneity of Periodic Fevers|journal=The American Journal of Human Genetics|volume=69|issue=2|year=2001|pages=301–314|issn=00029297|doi=10.1086/321976}}</ref><ref name="QuinteroSaba2019">{{cite journal|last1=Quintero|first1=Javier|last2=Saba|first2=Jihan|last3=Garcia|first3=Carlos|title=Tumor Necrosis Factor Receptor-1 Associated Periodic Syndrome: Case Report and Review of an Auto-inflammatory Disorder|journal=Cureus|year=2019|issn=2168-8184|doi=10.7759/cureus.3916}}</ref><ref name="ChenYu2014">{{cite journal|last1=Chen|first1=Yun-Ju|last2=Yu|first2=Hsin-Hui|last3=Yang|first3=Yao-Hsu|last4=Lau|first4=Yu-Lung|last5=Lee|first5=Wen-I|last6=Chiang|first6=Bor-Luen|title=Recurrent abdominal pain as the presentation of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in an Asian girl: A case report and review of the literature|journal=Journal of Microbiology, Immunology and Infection|volume=47|issue=6|year=2014|pages=550–554|issn=16841182|doi=10.1016/j.jmii.2012.07.003}}</ref> | *Although, first described in Ireland, this [[disorder]] has also been reported in other countries. However, it is especially common in Western countries rather than Asian countries.<ref name="AksentijevichGalon2001">{{cite journal|last1=Aksentijevich|first1=Ivona|last2=Galon|first2=Jérôme|last3=Soares|first3=Miguel|last4=Mansfield|first4=Elizabeth|last5=Hull|first5=Keith|last6=Oh|first6=Hye-Hyun|last7=Goldbach-Mansky|first7=Raphaela|last8=Dean|first8=Jane|last9=Athreya|first9=Balu|last10=Reginato|first10=Antonio J.|last11=Henrickson|first11=Michael|last12=Pons-Estel|first12=Bernardo|last13=O’Shea|first13=John J.|last14=Kastner|first14=Daniel L.|title=The Tumor-Necrosis-Factor Receptor–Associated Periodic Syndrome: New Mutations in TNFRSF1A, Ancestral Origins, Genotype-Phenotype Studies, and Evidence for Further Genetic Heterogeneity of Periodic Fevers|journal=The American Journal of Human Genetics|volume=69|issue=2|year=2001|pages=301–314|issn=00029297|doi=10.1086/321976}}</ref><ref name="QuinteroSaba2019">{{cite journal|last1=Quintero|first1=Javier|last2=Saba|first2=Jihan|last3=Garcia|first3=Carlos|title=Tumor Necrosis Factor Receptor-1 Associated Periodic Syndrome: Case Report and Review of an Auto-inflammatory Disorder|journal=Cureus|year=2019|issn=2168-8184|doi=10.7759/cureus.3916}}</ref><ref name="ChenYu2014">{{cite journal|last1=Chen|first1=Yun-Ju|last2=Yu|first2=Hsin-Hui|last3=Yang|first3=Yao-Hsu|last4=Lau|first4=Yu-Lung|last5=Lee|first5=Wen-I|last6=Chiang|first6=Bor-Luen|title=Recurrent abdominal pain as the presentation of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in an Asian girl: A case report and review of the literature|journal=Journal of Microbiology, Immunology and Infection|volume=47|issue=6|year=2014|pages=550–554|issn=16841182|doi=10.1016/j.jmii.2012.07.003}}</ref> | ||
==Risk Factors== | ==Risk Factors== | ||
*There are no established risk factors for TNF receptor associated periodic syndrome. | *There are no established [[risk factors]] for TNF receptor associated periodic syndrome. | ||
==Screening== | ==Screening== | ||
There is insufficient evidence to recommend routine [[screening]] for | *There is insufficient evidence to recommend routine [[screening]] for TNF receptor-associated periodic syndrome. | ||
==Natural History, Complications, and Prognosis== | ==Natural History, Complications, and Prognosis== | ||
*The clinically important complication of TNF receptor associated periodic syndrome is amyloidosis which results from the | *The clinically important [[complication]] of TNF receptor associated periodic syndrome is [[amyloidosis]] which results from the continuous elevation of [[serum amyloid A]] ([[Serum amyloid A|SAA]]).<ref name="AgannaHammond2003">{{cite journal|last1=Aganna|first1=Ebun|last2=Hammond|first2=Linda|last3=Hawkins|first3=Philip N.|last4=Aldea|first4=Anna|last5=McKee|first5=Shane A.|last6=van Amstel|first6=Hans Kristian Ploos|last7=Mischung|first7=Claudia|last8=Kusuhara|first8=Koichi|last9=Saulsbury|first9=Frank T.|last10=Lachmann|first10=Helen J.|last11=Bybee|first11=Alison|last12=McDermott|first12=Elizabeth M.|last13=La Regina|first13=Micaela|last14=Arostegui|first14=Juan I.|last15=Campistol|first15=Josep M.|last16=Worthington|first16=Sharron|last17=High|first17=Kevin P.|last18=Molloy|first18=Michael G.|last19=Baker|first19=Nicholas|last20=Bidwell|first20=Jeff L.|last21=Castañer|first21=José L.|last22=Whiteford|first22=Margo L.|last23=Janssens-Korpola|first23=P. L.|last24=Manna|first24=Raffaele|last25=Powell|first25=Richard J.|last26=Woo|first26=Patricia|last27=Solis|first27=Pilar|last28=Minden|first28=Kirsten|last29=Frenkel|first29=Joost|last30=Yagüe|first30=Jordi|last31=Mirakian|first31=Rita M.|last32=Hitman|first32=Graham A.|last33=McDermott|first33=Michael F.|title=Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes|journal=Arthritis & Rheumatism|volume=48|issue=9|year=2003|pages=2632–2644|issn=00043591|doi=10.1002/art.11215}}</ref> | ||
*It is estimated that 10-20% of the individuals with TRAPS may develop [[amyloidosis]].<ref name="HoffmanSimon2009">{{cite journal|last1=Hoffman|first1=Hal M.|last2=Simon|first2=Anna|title=Recurrent febrile syndromes—what a rheumatologist needs to know|journal=Nature Reviews Rheumatology|volume=5|issue=5|year=2009|pages=249–256|issn=1759-4790|doi=10.1038/nrrheum.2009.40}}</ref> | |||
*[[Mutations]] involving [[cysteine]] substitution are more commonly associated with [[amyloidosis]].<ref name="AksentijevichGalon2001">{{cite journal|last1=Aksentijevich|first1=Ivona|last2=Galon|first2=Jérôme|last3=Soares|first3=Miguel|last4=Mansfield|first4=Elizabeth|last5=Hull|first5=Keith|last6=Oh|first6=Hye-Hyun|last7=Goldbach-Mansky|first7=Raphaela|last8=Dean|first8=Jane|last9=Athreya|first9=Balu|last10=Reginato|first10=Antonio J.|last11=Henrickson|first11=Michael|last12=Pons-Estel|first12=Bernardo|last13=O’Shea|first13=John J.|last14=Kastner|first14=Daniel L.|title=The Tumor-Necrosis-Factor Receptor–Associated Periodic Syndrome: New Mutations in TNFRSF1A, Ancestral Origins, Genotype-Phenotype Studies, and Evidence for Further Genetic Heterogeneity of Periodic Fevers|journal=The American Journal of Human Genetics|volume=69|issue=2|year=2001|pages=301–314|issn=00029297|doi=10.1086/321976}}</ref> | |||
==Diagnosis== | ==Diagnosis== | ||
===Diagnostic Study of Choice=== | ===Diagnostic Study of Choice=== | ||
*[[Diagnosis]] is based on the [[clinical]] features. In 2017, Eurofever registry developed a set of criteria for the diagnosis of the four major [[Periodic fever syndrome|periodic fever syndromes]]. Table below is the [[diagnostic criteria]] for TRAPS.<ref name="FedericiSormani2015">{{cite journal|last1=Federici|first1=Silvia|last2=Sormani|first2=Maria Pia|last3=Ozen|first3=Seza|last4=Lachmann|first4=Helen J|last5=Amaryan|first5=Gayane|last6=Woo|first6=Patricia|last7=Koné-Paut|first7=Isabelle|last8=Dewarrat|first8=Natacha|last9=Cantarini|first9=Luca|last10=Insalaco|first10=Antonella|last11=Uziel|first11=Yosef|last12=Rigante|first12=Donato|last13=Quartier|first13=Pierre|last14=Demirkaya|first14=Erkan|last15=Herlin|first15=Troels|last16=Meini|first16=Antonella|last17=Fabio|first17=Giovanna|last18=Kallinich|first18=Tilmann|last19=Martino|first19=Silvana|last20=Butbul|first20=Aviel Yonatan|last21=Olivieri|first21=Alma|last22=Kuemmerle-Deschner|first22=Jasmin|last23=Neven|first23=Benedicte|last24=Simon|first24=Anna|last25=Ozdogan|first25=Huri|last26=Touitou|first26=Isabelle|last27=Frenkel|first27=Joost|last28=Hofer|first28=Michael|last29=Martini|first29=Alberto|last30=Ruperto|first30=Nicolino|last31=Gattorno|first31=Marco|title=Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers|journal=Annals of the Rheumatic Diseases|volume=74|issue=5|year=2015|pages=799–805|issn=0003-4967|doi=10.1136/annrheumdis-2014-206580}}</ref> | *[[Diagnosis]] is based on the [[clinical]] features. In 2017, Eurofever registry developed a set of [[Criterion|criteria]] for the [[diagnosis]] of the four major [[Periodic fever syndrome|periodic fever syndromes]]. Table below is the [[diagnostic criteria]] for TRAPS.<ref name="FedericiSormani2015">{{cite journal|last1=Federici|first1=Silvia|last2=Sormani|first2=Maria Pia|last3=Ozen|first3=Seza|last4=Lachmann|first4=Helen J|last5=Amaryan|first5=Gayane|last6=Woo|first6=Patricia|last7=Koné-Paut|first7=Isabelle|last8=Dewarrat|first8=Natacha|last9=Cantarini|first9=Luca|last10=Insalaco|first10=Antonella|last11=Uziel|first11=Yosef|last12=Rigante|first12=Donato|last13=Quartier|first13=Pierre|last14=Demirkaya|first14=Erkan|last15=Herlin|first15=Troels|last16=Meini|first16=Antonella|last17=Fabio|first17=Giovanna|last18=Kallinich|first18=Tilmann|last19=Martino|first19=Silvana|last20=Butbul|first20=Aviel Yonatan|last21=Olivieri|first21=Alma|last22=Kuemmerle-Deschner|first22=Jasmin|last23=Neven|first23=Benedicte|last24=Simon|first24=Anna|last25=Ozdogan|first25=Huri|last26=Touitou|first26=Isabelle|last27=Frenkel|first27=Joost|last28=Hofer|first28=Michael|last29=Martini|first29=Alberto|last30=Ruperto|first30=Nicolino|last31=Gattorno|first31=Marco|title=Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers|journal=Annals of the Rheumatic Diseases|volume=74|issue=5|year=2015|pages=799–805|issn=0003-4967|doi=10.1136/annrheumdis-2014-206580}}</ref> | ||
{| border="3" | {| border="3" | ||
|+ | |+ | ||
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF|Presence}} !! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF|Score}} | ! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF|Presence}} !! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF|Score}} | ||
|- | |- | ||
! style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=" | ! style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="left" |Periorbital oedema | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |21 | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |21 | ||
|- | |- | ||
! style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=" | ! style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="left" |Duration of episodes >6 days | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |19 | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |19 | ||
|- | |- | ||
! style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=" | ! style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="left" |Migratory rash | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |18 | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |18 | ||
|- | |- | ||
! style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=" | ! style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="left" |Myalgia | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |6 | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |6 | ||
|- | |- | ||
! style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=" | ! style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="left" |Reletavies affected | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |7 | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |7 | ||
|- | |- | ||
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF|Absence}} !! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF|Score}} | ! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF|Absence}} !! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF|Score}} | ||
|- | |- | ||
! style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=" | ! style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="left" |Vomiting | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |14 | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |14 | ||
|- | |- | ||
! style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=" | ! style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="left" |Aphthous stomatitis | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |15 | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |15 | ||
|} | |} | ||
*The cut-off value for the [[diagnosis]] of TRAPS is score equal or higher than 43 scores. | |||
*The overall [[sensitivity]] and [[specificity]] of this set of criteria for the [[diagnosis]] of this [[disorder]] is 59% and 84%, respectively. | *The overall [[sensitivity]] and [[specificity]] of this set of criteria for the [[diagnosis]] of this [[disorder]] is 59% and 84%, respectively. | ||
*The gold standard [[Diagnostic study of choice|diagnostic study]] for TNF receptor associated periodic syndrome is the [[genetic analysis]].<ref name="QuinteroSaba2019">{{cite journal|last1=Quintero|first1=Javier|last2=Saba|first2=Jihan|last3=Garcia|first3=Carlos|title=Tumor Necrosis Factor Receptor-1 Associated Periodic Syndrome: Case Report and Review of an Auto-inflammatory Disorder|journal=Cureus|year=2019|issn=2168-8184|doi=10.7759/cureus.3916}}</ref> | *The [[Gold standard (test)|gold standard]] [[Diagnostic study of choice|diagnostic study]] for TNF receptor associated periodic syndrome is the [[genetic analysis]].<ref name="QuinteroSaba2019">{{cite journal|last1=Quintero|first1=Javier|last2=Saba|first2=Jihan|last3=Garcia|first3=Carlos|title=Tumor Necrosis Factor Receptor-1 Associated Periodic Syndrome: Case Report and Review of an Auto-inflammatory Disorder|journal=Cureus|year=2019|issn=2168-8184|doi=10.7759/cureus.3916}}</ref> | ||
===History and Symptoms=== | ===History and Symptoms=== | ||
*The hallmark of TNF-a receptor-associated periodic syndrome is recurrent fever episodes lasting 1 to 4 weeks or more. [[Fever]] is accompanied by other [[symptoms]] including but not limited to | *The hallmark of TNF-a receptor-associated periodic syndrome is recurrent [[fever]] episodes lasting 1 to 4 weeks or more. [[Fever]] is accompanied by other [[symptoms]] including but not limited to [[skin rash]], [[abdominal pain]], [[diarrhea]], puffy eyes (due to [[periorbital edema]]), [[Myalgia|migrating muscle and joint pain]], and [[Conjunctivitis|erythema of the eye]].<ref name="CantariniIacoponi2011">{{cite journal|last1=Cantarini|first1=L.|last2=Iacoponi|first2=F.|last3=Lucherini|first3=O.M.|last4=Obici|first4=L.|last5=Brizi|first5=M.G.|last6=Cimaz|first6=R.|last7=Rigante|first7=D.|last8=Benucci|first8=M.|last9=Sebastiani|first9=G.D.|last10=Brucato|first10=A.|last11=Sabadini|first11=L.|last12=Simonini|first12=G.|last13=Giani|first13=T.|last14=Pasini|first14=F. Laghi|last15=Baldari|first15=C.T.|last16=Bellisai|first16=F.|last17=Valentini|first17=G.|last18=Bombardieri|first18=S.|last19=Paolazzi|first19=G|last20=Galeazzi|first20=M.|title=Validation of a Diagnostic Score for the Diagnosis of Autoinflammatory Diseases in Adults|journal=International Journal of Immunopathology and Pharmacology|volume=24|issue=3|year=2011|pages=695–702|issn=0394-6320|doi=10.1177/039463201102400315}}</ref> | ||
===Physical Examination=== | ===Physical Examination=== | ||
Common [[physical examination]] findings of TNF receptor-associated periodic syndrome include [[fever]], [[skin rash]], [[lymphadenopathy]], and [[splenomegaly]].<ref name="CantariniIacoponi2011">{{cite journal|last1=Cantarini|first1=L.|last2=Iacoponi|first2=F.|last3=Lucherini|first3=O.M.|last4=Obici|first4=L.|last5=Brizi|first5=M.G.|last6=Cimaz|first6=R.|last7=Rigante|first7=D.|last8=Benucci|first8=M.|last9=Sebastiani|first9=G.D.|last10=Brucato|first10=A.|last11=Sabadini|first11=L.|last12=Simonini|first12=G.|last13=Giani|first13=T.|last14=Pasini|first14=F. Laghi|last15=Baldari|first15=C.T.|last16=Bellisai|first16=F.|last17=Valentini|first17=G.|last18=Bombardieri|first18=S.|last19=Paolazzi|first19=G|last20=Galeazzi|first20=M.|title=Validation of a Diagnostic Score for the Diagnosis of Autoinflammatory Diseases in Adults|journal=International Journal of Immunopathology and Pharmacology|volume=24|issue=3|year=2011|pages=695–702|issn=0394-6320|doi=10.1177/039463201102400315}}</ref> | *Common [[physical examination]] findings of TNF receptor-associated periodic syndrome include [[fever]], [[skin rash]], [[lymphadenopathy]], and [[splenomegaly]].<ref name="CantariniIacoponi2011">{{cite journal|last1=Cantarini|first1=L.|last2=Iacoponi|first2=F.|last3=Lucherini|first3=O.M.|last4=Obici|first4=L.|last5=Brizi|first5=M.G.|last6=Cimaz|first6=R.|last7=Rigante|first7=D.|last8=Benucci|first8=M.|last9=Sebastiani|first9=G.D.|last10=Brucato|first10=A.|last11=Sabadini|first11=L.|last12=Simonini|first12=G.|last13=Giani|first13=T.|last14=Pasini|first14=F. Laghi|last15=Baldari|first15=C.T.|last16=Bellisai|first16=F.|last17=Valentini|first17=G.|last18=Bombardieri|first18=S.|last19=Paolazzi|first19=G|last20=Galeazzi|first20=M.|title=Validation of a Diagnostic Score for the Diagnosis of Autoinflammatory Diseases in Adults|journal=International Journal of Immunopathology and Pharmacology|volume=24|issue=3|year=2011|pages=695–702|issn=0394-6320|doi=10.1177/039463201102400315}}</ref> | ||
*Cutaneous manifestations of TRAPS include an [[erythematous rash]] that overlies an area with [[myalgia]], | **[[Cutaneous]] manifestations of TRAPS include an [[erythematous rash]] that overlies an area with [[myalgia]], [[erysipelas]]-like [[erythema]], and [[urticaria]]. | ||
*Eye involvement is characteristics for this [[disease]] among other [[Periodic fever syndrome|autoinflammatory diseases]] and may manifest with [[conjunctivitis]], [[periorbital edema]], and [[uveitis]]. | **Eye involvement is characteristics for this [[disease]] among other [[Periodic fever syndrome|autoinflammatory diseases]] and may manifest with [[conjunctivitis]], [[periorbital edema]], and [[uveitis]]. | ||
*Signs consistent with acute abdomen may also be present.<ref name="ChenYu2014">{{cite journal|last1=Chen|first1=Yun-Ju|last2=Yu|first2=Hsin-Hui|last3=Yang|first3=Yao-Hsu|last4=Lau|first4=Yu-Lung|last5=Lee|first5=Wen-I|last6=Chiang|first6=Bor-Luen|title=Recurrent abdominal pain as the presentation of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in an Asian girl: A case report and review of the literature|journal=Journal of Microbiology, Immunology and Infection|volume=47|issue=6|year=2014|pages=550–554|issn=16841182|doi=10.1016/j.jmii.2012.07.003}}</ref> | **[[Signs]] consistent with [[acute abdomen]] may also be present.<ref name="ChenYu2014">{{cite journal|last1=Chen|first1=Yun-Ju|last2=Yu|first2=Hsin-Hui|last3=Yang|first3=Yao-Hsu|last4=Lau|first4=Yu-Lung|last5=Lee|first5=Wen-I|last6=Chiang|first6=Bor-Luen|title=Recurrent abdominal pain as the presentation of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in an Asian girl: A case report and review of the literature|journal=Journal of Microbiology, Immunology and Infection|volume=47|issue=6|year=2014|pages=550–554|issn=16841182|doi=10.1016/j.jmii.2012.07.003}}</ref> | ||
===Laboratory Findings=== | ===Laboratory Findings=== | ||
*An elevated concentration of blood acute phase reactants are observed both during and in between inflammatory attacks.<ref name="ChenYu2014">{{cite journal|last1=Chen|first1=Yun-Ju|last2=Yu|first2=Hsin-Hui|last3=Yang|first3=Yao-Hsu|last4=Lau|first4=Yu-Lung|last5=Lee|first5=Wen-I|last6=Chiang|first6=Bor-Luen|title=Recurrent abdominal pain as the presentation of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in an Asian girl: A case report and review of the literature|journal=Journal of Microbiology, Immunology and Infection|volume=47|issue=6|year=2014|pages=550–554|issn=16841182|doi=10.1016/j.jmii.2012.07.003}}</ref> | *An elevated concentration of [[blood]] [[Acute phase reactant|acute phase reactants]] are observed both during and in between [[inflammatory]] attacks.<ref name="ChenYu2014">{{cite journal|last1=Chen|first1=Yun-Ju|last2=Yu|first2=Hsin-Hui|last3=Yang|first3=Yao-Hsu|last4=Lau|first4=Yu-Lung|last5=Lee|first5=Wen-I|last6=Chiang|first6=Bor-Luen|title=Recurrent abdominal pain as the presentation of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in an Asian girl: A case report and review of the literature|journal=Journal of Microbiology, Immunology and Infection|volume=47|issue=6|year=2014|pages=550–554|issn=16841182|doi=10.1016/j.jmii.2012.07.003}}</ref> | ||
*An elevated level of serum TNF-α, C3, and C4 have also been reported. | *An elevated level of [[serum]] [[TNF-α]], [[C3 (complement)|C3]], and [[Complement|C4]] have also been reported. | ||
===Electrocardiogram=== | ===Electrocardiogram=== | ||
*There are no [[ECG]] findings associated with TNF receptor-associated periodic syndrome. | *There are no [[ECG]] findings associated with TNF receptor-associated periodic syndrome. | ||
| Line 106: | Line 110: | ||
===CT scan=== | ===CT scan=== | ||
*There are no [[CT scan]] findings associated with TNF receptor-associated periodic syndrome. | *There are no [[CT scan]] findings associated with TNF receptor-associated periodic syndrome. | ||
*However, para-aortic and mesenteric lymphadenopathies have been reported in one case.<ref name="ChenYu2014">{{cite journal|last1=Chen|first1=Yun-Ju|last2=Yu|first2=Hsin-Hui|last3=Yang|first3=Yao-Hsu|last4=Lau|first4=Yu-Lung|last5=Lee|first5=Wen-I|last6=Chiang|first6=Bor-Luen|title=Recurrent abdominal pain as the presentation of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in an Asian girl: A case report and review of the literature|journal=Journal of Microbiology, Immunology and Infection|volume=47|issue=6|year=2014|pages=550–554|issn=16841182|doi=10.1016/j.jmii.2012.07.003}}</ref> | *However, [[Paraaortic lymph node|para-aortic]] and [[mesenteric]] [[Lymphadenopathy|lymphadenopathies]] have been reported in one case.<ref name="ChenYu2014">{{cite journal|last1=Chen|first1=Yun-Ju|last2=Yu|first2=Hsin-Hui|last3=Yang|first3=Yao-Hsu|last4=Lau|first4=Yu-Lung|last5=Lee|first5=Wen-I|last6=Chiang|first6=Bor-Luen|title=Recurrent abdominal pain as the presentation of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in an Asian girl: A case report and review of the literature|journal=Journal of Microbiology, Immunology and Infection|volume=47|issue=6|year=2014|pages=550–554|issn=16841182|doi=10.1016/j.jmii.2012.07.003}}</ref> | ||
===MRI=== | ===MRI=== | ||
*There are no [[MRI]] findings associated with TNF receptor-associated periodic syndrome. | *There are no [[MRI]] findings associated with TNF receptor-associated periodic syndrome. | ||
| Line 113: | Line 117: | ||
===Other Diagnostic Studies=== | ===Other Diagnostic Studies=== | ||
*There are no other [[diagnostic]] studies associated with TNF receptor-associated periodic syndrome. | *There are no other [[diagnostic]] studies associated with TNF receptor-associated periodic syndrome. | ||
==Treatment== | ==Treatment== | ||
===Medical Therapy=== | ===Medical Therapy=== | ||
*Several medications have been studied for the treatment of TRAPS including high dose corticosteroids, [[etanercept]], and [[infliximab]].<ref name="ChenYu2014">{{cite journal|last1=Chen|first1=Yun-Ju|last2=Yu|first2=Hsin-Hui|last3=Yang|first3=Yao-Hsu|last4=Lau|first4=Yu-Lung|last5=Lee|first5=Wen-I|last6=Chiang|first6=Bor-Luen|title=Recurrent abdominal pain as the presentation of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in an Asian girl: A case report and review of the literature|journal=Journal of Microbiology, Immunology and Infection|volume=47|issue=6|year=2014|pages=550–554|issn=16841182|doi=10.1016/j.jmii.2012.07.003}}</ref> | *Several medications have been studied for the treatment of TRAPS including high dose [[Corticosteroid|corticosteroids]], [[etanercept]], and [[infliximab]].<ref name="ChenYu2014">{{cite journal|last1=Chen|first1=Yun-Ju|last2=Yu|first2=Hsin-Hui|last3=Yang|first3=Yao-Hsu|last4=Lau|first4=Yu-Lung|last5=Lee|first5=Wen-I|last6=Chiang|first6=Bor-Luen|title=Recurrent abdominal pain as the presentation of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in an Asian girl: A case report and review of the literature|journal=Journal of Microbiology, Immunology and Infection|volume=47|issue=6|year=2014|pages=550–554|issn=16841182|doi=10.1016/j.jmii.2012.07.003}}</ref> | ||
*Response to the | *Response to the aforementioned treatment options reported to be different in different cases. | ||
*[[Etanercept]] has been reported to effectively reduce the severity of attacks as well as the risk of [[amyloidosis]] development.<ref name="DreweMcDermott2000">{{cite journal|last1=Drewe|first1=Elizabeth|last2=McDermott|first2=Elizabeth M.|last3=Powell|first3=Richard J.|title=Treatment of the Nephrotic Syndrome with Etanercept in Patients with the Tumor Necrosis Factor Receptor–Associated Periodic Syndrome|journal=New England Journal of Medicine|volume=343|issue=14|year=2000|pages=1044–1045|issn=0028-4793|doi=10.1056/NEJM200010053431412}}</ref> | |||
===Surgery=== | ===Surgery=== | ||
*[[Surgery|Surgical intervention]] is not recommended for the management of TNF receptor-associated periodic syndrome. | *[[Surgery|Surgical intervention]] is not recommended for the management of TNF receptor-associated periodic syndrome. | ||
| Line 125: | Line 131: | ||
== References == | == References == | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Rheumatology]] | [[Category:Rheumatology]] | ||
[[fr:TNF receptor-associated periodic syndrome]] | [[fr:TNF receptor-associated periodic syndrome]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 19:49, 24 October 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2]
Synonyms and keywords: Tumor necrosis factor receptor-associated periodic syndrome (TRAPS); Familial Hibernian fever; FHF; Familial Caledonian fever
Overview
TNF receptor-associated periodic syndrome (also known as TRAPS or familial Hibernian fever) is a periodic fever syndrome associated with mutation in a receptor for the molecule tumor necrosis factor (TNF). Since this disease first described in Ireland, it was called Hibernian fever in reference to the ancient Latin name for Ireland, Hibernia.
Historical Perspective
- TNF receptor-associated periodic syndrome was first described by Dr. Williamson in 1982 in an Irish-Scottish family affected by an autosomal dominant pattern disorder.[1]
- The association between the TNFRSF1A gene locus and TNF receptor-associated periodic syndrome was made in 1998.[2]
- In 2003, Dr. Weyhreter was the first to use etanercept (a fusion protein of the extracellular domain of TNFRSF1A and the Fc portion of IgG1) for the treatment of TRAPS, which results successful treatment of the patient.[3]
Classification
- There is no established system for the classification of TNF receptor associated periodic syndrome.
Pathophysiology
- TNF receptor associated periodic syndrome is an autosomal dominant inherited disorder due to mutation in the TNF Receptor Super Family 1A (TNFRSF1A) gene.[4]
- Mutation in the gene is associated with abnormally structured TNF receptor which leads to impaired TNF-a binding and subsequent abnormal function of this factor in apoptosis and NF-κB pathway. However, the exact mechanisms causing febrile episodes remain to be cleared.[5][6][7]
- Another hypotheses is that mutation in the gene results in intracellular accumulation of the receptor. This abnormal accumulation of the receptor leads to an exaggerated inflammatory response to low levels of innate stimuli such as lipopolysaccharide (LPS).[8]
Differentiating TNF receptor associated periodic syndrome from Other Diseases
- TNF receptor associated periodic syndrome must be differentiated from other diseases that cause fever, abdominal pain, and arthritis, such as infections, other autoinflammatory diseases, and autoimmune disorders.
- For more information on the differential diagnosis of TNF receptor associated periodic syndrome please click here
Epidemiology and Demographics
- This disorder is the second most common inflammatory disorder after familial mediterranean fever (FMF).
- The incidence/prevalence of TNF receptor associated periodic syndrome is approximately 0.06 per 100,000 individuals of 16 years of age or younger worldwide.[9]
- Approximately, 1000 cases have been reported worldwide.[10]
- TNF receptor associated periodic syndrome commonly affects individuals of 3 years of age. However, due to overlap of the symptoms with other disorders and possible misdiagnosis, it may be diagnosed in adolescence or adulthood. In addition, the variants with low penetrance tend to manifest later in the adult life.[11]
- Although more common in children, reports of patients developing TRAPS in old age are available.[12]
- Although, first described in Ireland, this disorder has also been reported in other countries. However, it is especially common in Western countries rather than Asian countries.[13][14][15]
Risk Factors
- There are no established risk factors for TNF receptor associated periodic syndrome.
Screening
- There is insufficient evidence to recommend routine screening for TNF receptor-associated periodic syndrome.
Natural History, Complications, and Prognosis
- The clinically important complication of TNF receptor associated periodic syndrome is amyloidosis which results from the continuous elevation of serum amyloid A (SAA).[16]
- It is estimated that 10-20% of the individuals with TRAPS may develop amyloidosis.[17]
- Mutations involving cysteine substitution are more commonly associated with amyloidosis.[13]
Diagnosis
Diagnostic Study of Choice
- Diagnosis is based on the clinical features. In 2017, Eurofever registry developed a set of criteria for the diagnosis of the four major periodic fever syndromes. Table below is the diagnostic criteria for TRAPS.[18]
| Presence | Score |
|---|---|
| Periorbital oedema | 21 |
| Duration of episodes >6 days | 19 |
| Migratory rash | 18 |
| Myalgia | 6 |
| Reletavies affected | 7 |
| Absence | Score |
| Vomiting | 14 |
| Aphthous stomatitis | 15 |
- The cut-off value for the diagnosis of TRAPS is score equal or higher than 43 scores.
- The overall sensitivity and specificity of this set of criteria for the diagnosis of this disorder is 59% and 84%, respectively.
- The gold standard diagnostic study for TNF receptor associated periodic syndrome is the genetic analysis.[14]
History and Symptoms
- The hallmark of TNF-a receptor-associated periodic syndrome is recurrent fever episodes lasting 1 to 4 weeks or more. Fever is accompanied by other symptoms including but not limited to skin rash, abdominal pain, diarrhea, puffy eyes (due to periorbital edema), migrating muscle and joint pain, and erythema of the eye.[11]
Physical Examination
- Common physical examination findings of TNF receptor-associated periodic syndrome include fever, skin rash, lymphadenopathy, and splenomegaly.[11]
- Cutaneous manifestations of TRAPS include an erythematous rash that overlies an area with myalgia, erysipelas-like erythema, and urticaria.
- Eye involvement is characteristics for this disease among other autoinflammatory diseases and may manifest with conjunctivitis, periorbital edema, and uveitis.
- Signs consistent with acute abdomen may also be present.[15]
Laboratory Findings
- An elevated concentration of blood acute phase reactants are observed both during and in between inflammatory attacks.[15]
- An elevated level of serum TNF-α, C3, and C4 have also been reported.
Electrocardiogram
- There are no ECG findings associated with TNF receptor-associated periodic syndrome.
X-ray
- There are no x-ray findings associated with TNF receptor-associated periodic syndrome.
Echocardiography or Ultrasound
- There are no echocardiography/ultrasound findings associated with TNF receptor-associated periodic syndrome.
CT scan
- There are no CT scan findings associated with TNF receptor-associated periodic syndrome.
- However, para-aortic and mesenteric lymphadenopathies have been reported in one case.[15]
MRI
- There are no MRI findings associated with TNF receptor-associated periodic syndrome.
Other Imaging Findings
- There are no other imaging findings associated with TNF receptor-associated periodic syndrome.
Other Diagnostic Studies
- There are no other diagnostic studies associated with TNF receptor-associated periodic syndrome.
Treatment
Medical Therapy
- Several medications have been studied for the treatment of TRAPS including high dose corticosteroids, etanercept, and infliximab.[15]
- Response to the aforementioned treatment options reported to be different in different cases.
- Etanercept has been reported to effectively reduce the severity of attacks as well as the risk of amyloidosis development.[19]
Surgery
- Surgical intervention is not recommended for the management of TNF receptor-associated periodic syndrome.
Primary Prevention
- There are no established measures for the primary prevention of TNF receptor-associated periodic syndrome.
Secondary Prevention
- There are no established measures for the secondary prevention of TNF receptor-associated periodic syndrome.
References
- ↑ L. M. Williamson, D. Hull, R. Mehta, W. G. Reeves, B. H. Robinson & P. J. Toghill (1982). "Familial Hibernian fever". The Quarterly journal of medicine. 51 (204): 469–480. PMID 7156325.
- ↑ McDermott, Michael F.; Ogunkolade, B. William; McDermott, Elizabeth M.; Jones, Lisa C.; Wan, Ying; Quane, Kathleen A.; McCarthy, John; Phelan, Mark; Molloy, Michael G.; Powell, Richard J.; Amos, Christopher I.; Hitman, Graham A. (1998). "Linkage of Familial Hibernian Fever to Chromosome 12p13". The American Journal of Human Genetics. 62 (6): 1446–1451. doi:10.1086/301886. ISSN 0002-9297.
- ↑ Weyhreter, Heike; Schwartz, Marianne; Kristensen, Tim D.; Valerius, Niels H.; Paerregaard, Anders (2003). "A new mutation causing autosomal dominant periodic fever syndrome in a Danish family". The Journal of Pediatrics. 142 (2): 191–193. doi:10.1067/mpd.2003.15. ISSN 0022-3476.
- ↑ M. F. McDermott, I. Aksentijevich, J. Galon, E. M. McDermott, B. W. Ogunkolade, M. Centola, E. Mansfield, M. Gadina, L. Karenko, T. Pettersson, J. McCarthy, D. M. Frucht, M. Aringer, Y. Torosyan, A. M. Teppo, M. Wilson, H. M. Karaarslan, Y. Wan, I. Todd, G. Wood, R. Schlimgen, T. R. Kumarajeewa, S. M. Cooper, J. P. Vella, C. I. Amos, J. Mulley, K. A. Quane, M. G. Molloy, A. Ranki, R. J. Powell, G. A. Hitman, J. J. O'Shea & D. L. Kastner (1999). "Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes". Cell. 97 (1): 133–144. PMID 10199409. Unknown parameter
|month=ignored (help) - ↑ Nedjai, Belinda; Hitman, Graham A.; Yousaf, Nasim; Chernajovsky, Yuti; Stjernberg-Salmela, Susanna; Pettersson, Tom; Ranki, Annamari; Hawkins, Philip N.; Arkwright, Peter D.; McDermott, Michael F.; Turner, Mark D. (2008). "Abnormal tumor necrosis factor receptor I cell surface expression and NF-κB activation in tumor necrosis factor receptor–associated periodic syndrome". Arthritis & Rheumatism. 58 (1): 273–283. doi:10.1002/art.23123. ISSN 0004-3591.
- ↑ D'Osualdo, Andrea; Ferlito, Francesca; Prigione, Ignazia; Obici, Laura; Meini, Antonella; Zulian, Francesco; Pontillo, Alessandra; Corona, Fabrizia; Barcellona, Roberto; Duca, Marco Di; Santamaria, Giuseppe; Traverso, Francesco; Picco, Paolo; Baldi, Maurizia; Plebani, Alessandro; Ravazzolo, Roberto; Ceccherini, Isabella; Martini, Alberto; Gattorno, Marco (2006). "Neutrophils from patients withTNFRSF1A mutations display resistance to tumor necrosis factor–induced apoptosis: Pathogenetic and clinical implications". Arthritis & Rheumatism. 54 (3): 998–1008. doi:10.1002/art.21657. ISSN 0004-3591.
- ↑ Churchman, S M; Church, L D; Savic, S; Coulthard, L R; Hayward, B; Nedjai, B; Turner, M D; Mathews, R J; Baguley, E; Hitman, G A; Gooi, H C; Wood, P M D; Emery, P; McDermott, M F (2007). "A novel TNFRSF1A splice mutation associated with increased nuclear factor appaB (NF- B) transcription factor activation in patients with tumour necrosis factor receptor associated periodic syndrome (TRAPS)". Annals of the Rheumatic Diseases. 67 (11): 1589–1595. doi:10.1136/ard.2007.078667. ISSN 0003-4967.
- ↑ Simon, A.; Park, H.; Maddipati, R.; Lobito, A. A.; Bulua, A. C.; Jackson, A. J.; Chae, J. J.; Ettinger, R.; de Koning, H. D.; Cruz, A. C.; Kastner, D. L.; Komarow, H.; Siegel, R. M. (2010). "Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome". Proceedings of the National Academy of Sciences. 107 (21): 9801–9806. doi:10.1073/pnas.0914118107. ISSN 0027-8424.
- ↑ Lainka, E.; Neudorf, U.; Lohse, P.; Timmann, C.; Stojanov, S.; Huss, K.; von Kries, R.; Niehues, T. (2009). "Incidence of TNFRSF1A mutations in German children: epidemiological, clinical and genetic characteristics". Rheumatology. 48 (8): 987–991. doi:10.1093/rheumatology/kep140. ISSN 1462-0324.
- ↑ "TRAPS - Genetics Home Reference - NIH".
- ↑ 11.0 11.1 11.2 Cantarini, L.; Iacoponi, F.; Lucherini, O.M.; Obici, L.; Brizi, M.G.; Cimaz, R.; Rigante, D.; Benucci, M.; Sebastiani, G.D.; Brucato, A.; Sabadini, L.; Simonini, G.; Giani, T.; Pasini, F. Laghi; Baldari, C.T.; Bellisai, F.; Valentini, G.; Bombardieri, S.; Paolazzi, G; Galeazzi, M. (2011). "Validation of a Diagnostic Score for the Diagnosis of Autoinflammatory Diseases in Adults". International Journal of Immunopathology and Pharmacology. 24 (3): 695–702. doi:10.1177/039463201102400315. ISSN 0394-6320.
- ↑ Sinožić, Dean; Toplak, Nataša; Milotić, Irena (2011). "Tumor Necrosis Factor Receptor-Associated Periodic Fever Syndrome in a 58-Year-Old Man". Journal of Clinical Rheumatology. 17 (6): 325–328. doi:10.1097/RHU.0b013e31822e092c. ISSN 1076-1608.
- ↑ 13.0 13.1 Aksentijevich, Ivona; Galon, Jérôme; Soares, Miguel; Mansfield, Elizabeth; Hull, Keith; Oh, Hye-Hyun; Goldbach-Mansky, Raphaela; Dean, Jane; Athreya, Balu; Reginato, Antonio J.; Henrickson, Michael; Pons-Estel, Bernardo; O’Shea, John J.; Kastner, Daniel L. (2001). "The Tumor-Necrosis-Factor Receptor–Associated Periodic Syndrome: New Mutations in TNFRSF1A, Ancestral Origins, Genotype-Phenotype Studies, and Evidence for Further Genetic Heterogeneity of Periodic Fevers". The American Journal of Human Genetics. 69 (2): 301–314. doi:10.1086/321976. ISSN 0002-9297.
- ↑ 14.0 14.1 Quintero, Javier; Saba, Jihan; Garcia, Carlos (2019). "Tumor Necrosis Factor Receptor-1 Associated Periodic Syndrome: Case Report and Review of an Auto-inflammatory Disorder". Cureus. doi:10.7759/cureus.3916. ISSN 2168-8184.
- ↑ 15.0 15.1 15.2 15.3 15.4 Chen, Yun-Ju; Yu, Hsin-Hui; Yang, Yao-Hsu; Lau, Yu-Lung; Lee, Wen-I; Chiang, Bor-Luen (2014). "Recurrent abdominal pain as the presentation of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in an Asian girl: A case report and review of the literature". Journal of Microbiology, Immunology and Infection. 47 (6): 550–554. doi:10.1016/j.jmii.2012.07.003. ISSN 1684-1182.
- ↑ Aganna, Ebun; Hammond, Linda; Hawkins, Philip N.; Aldea, Anna; McKee, Shane A.; van Amstel, Hans Kristian Ploos; Mischung, Claudia; Kusuhara, Koichi; Saulsbury, Frank T.; Lachmann, Helen J.; Bybee, Alison; McDermott, Elizabeth M.; La Regina, Micaela; Arostegui, Juan I.; Campistol, Josep M.; Worthington, Sharron; High, Kevin P.; Molloy, Michael G.; Baker, Nicholas; Bidwell, Jeff L.; Castañer, José L.; Whiteford, Margo L.; Janssens-Korpola, P. L.; Manna, Raffaele; Powell, Richard J.; Woo, Patricia; Solis, Pilar; Minden, Kirsten; Frenkel, Joost; Yagüe, Jordi; Mirakian, Rita M.; Hitman, Graham A.; McDermott, Michael F. (2003). "Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes". Arthritis & Rheumatism. 48 (9): 2632–2644. doi:10.1002/art.11215. ISSN 0004-3591.
- ↑ Hoffman, Hal M.; Simon, Anna (2009). "Recurrent febrile syndromes—what a rheumatologist needs to know". Nature Reviews Rheumatology. 5 (5): 249–256. doi:10.1038/nrrheum.2009.40. ISSN 1759-4790.
- ↑ Federici, Silvia; Sormani, Maria Pia; Ozen, Seza; Lachmann, Helen J; Amaryan, Gayane; Woo, Patricia; Koné-Paut, Isabelle; Dewarrat, Natacha; Cantarini, Luca; Insalaco, Antonella; Uziel, Yosef; Rigante, Donato; Quartier, Pierre; Demirkaya, Erkan; Herlin, Troels; Meini, Antonella; Fabio, Giovanna; Kallinich, Tilmann; Martino, Silvana; Butbul, Aviel Yonatan; Olivieri, Alma; Kuemmerle-Deschner, Jasmin; Neven, Benedicte; Simon, Anna; Ozdogan, Huri; Touitou, Isabelle; Frenkel, Joost; Hofer, Michael; Martini, Alberto; Ruperto, Nicolino; Gattorno, Marco (2015). "Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers". Annals of the Rheumatic Diseases. 74 (5): 799–805. doi:10.1136/annrheumdis-2014-206580. ISSN 0003-4967.
- ↑ Drewe, Elizabeth; McDermott, Elizabeth M.; Powell, Richard J. (2000). "Treatment of the Nephrotic Syndrome with Etanercept in Patients with the Tumor Necrosis Factor Receptor–Associated Periodic Syndrome". New England Journal of Medicine. 343 (14): 1044–1045. doi:10.1056/NEJM200010053431412. ISSN 0028-4793.